It is reported for SARS-CoV HLA-B*4601, HLA-B*0703, HLA-DR B1*1202 are activated [26], interaction with different MHC I and II allelic forms namely HLA-A*11:01, HLA-A*68:01, HLA-DRB1*01:01 and HLA-DRB1*07:01. CD4+ and CD8+ memory T cells. Based on prior literature, it is anticipated that it can persist for four years as in the case of SARS-CoV recovered individuals, show T-cell proliferation, DTH response, and production of IFN-γ [12]. We surmise that our screen can be more effective and useful. Primarily molecular docking reveals three Epitopes, but as we proceed to Molecular dynamic simulations, it reveals best interactions for two epitopes i.e., ITLCFTLKR and VYQLRARSV, with acceptable stability analyzed with the help of MDWeb and identified by using best available tools with easy-to-apply methods. One recent study was found to be focused on developing monoclonal antibodies like CR-3022 against the Spike protein of SARS-COV-2 that also exhibits interaction with ACE (Angiotensin Converting Enzyme) enzyme of the Human respiratory epithelium and requires complex neutralizing mechanisms for several binding domains [35], whereas in our study the putative T-cell epitopes can directly interact with MHC-Allelic sets that can be useful for developing immunization against SARS-COV-2. ProtParam [42] analysis further reveals the stability of the considered epitopes, and final revelation of one epitope ITLCFTLKR is screened out. This particular Epitope shows an instability index of 35.68 with a grand average of hydropathicity (GRAVY) calculated as 0.844, and the estimated half-life for this peptide was determined to be 20 h for mammalian reticulocytes.